Clinical Trials Begin for Anti-inflammatory Product
Links shared publicly online about this topic.
- 922total visits
Clinical Trials Begin for Anti-inflammatory Product
View full resource at hcplive.com
Tags: Pain, Clinical Trial, Surgery
Most Recently Shared on August 25, 2010 at 3:47 pm By:
Clinical Trials Begin for Anti-inflammatory Product http://hcp.lv/9DwF57
Mesoblast receives EMA clearance to initiate Revascor Phase 2 trial for heart attacks
news-medical.net — “Global regenerative medicine company, Mesoblast Limited, today announced that it had received clearance from the European Medicines Agency (EMA) to begin a 225-patient multi-center Phase 2 clinical trial in Europe for its lead cardiovascular product Revascor(TM) in conjunction with angioplasty and stent procedures to prevent heart failure after a major heart attack.” View full resource at news-medical.net
Most Recently Shared on September 5, 2011 at 1:44 pm By:
Stroke News: Mesoblast receives EMA clearance to initiate Revascor Phase 2 trial for heart attacks: Global reg... http://t.co/b9YvlwK
Australia’s Mesoblast receives nod to start first European trial of allogeneic stem cell treatment for heart attacks
news-medical.net — “Global regenerative medicine company, Mesoblast Limited, (ASX: MSB), today announced that it had received clearance from the European Medicines Agency (EMA) to begin a 225-patient multi-center Phase 2 clinical trial in Europe for its lead cardiovascular product Revascor™ in conjunction with angioplasty and stent procedures to prevent heart failure after a major heart attack. Revascor™ is an allogeneic, or “off-the-shelf”, adult stem cell product derived from Mesoblast's proprietary Mesenchym” View full resource at news-medical.net
Most Recently Shared on September 5, 2011 at 11:57 am By:
Australia’s Mesoblast receives nod to start first European trial of allogeneic stem cell treatment for heart att... http://t.co/bpIVYHM
InSite Vision Announces Positive Phase 1/2 Results For ISV-303 For The Reduction Of Pain And Inflammation After Cataract Surgery
medicalnewstoday.com — “InSite Vision Incorporated (OTCBB:INSV) announced top-line results from its recently completed Phase 1/2 clinical trial of ISV-303, a topical anti-inflammatory product intended to reduce the pain” View full resource at medicalnewstoday.com
Most Recently Shared on March 23, 2011 at 4:05 pm By:
MNT Pain News Pain Management and Health News
InSite Vision Announces Positive Phase 1/2 Results For ISV-303 For The Reduction Of Pain And Inflammation After Catara... http://mnt.to/3SDr
Psoriasis treatment trials begin; $10M GSK milestone payment to come
medcitynews.com — “GlaxoSmithKline could add a new psoriasis treatment to its arsenal of drugs if partner ChemoCentryx is successful developing a new product treating the condition. ChemoCentryx has entered human trials with its compound, triggering a $10 million milestone payment from GSK.” View full resource at medcitynews.com
Most Recently Shared on January 27, 2011 at 7:07 pm By:
National Psoriasis Foundation Dermatology and Health Organization
RT @PSOresearch #GSK & Chemocentryx begin a phase I trial of new anti-inflammatory small molecule for #psoriasis. http://tinyurl.com/672d54b
FDA accepts IND application to initiate human clinical trial to evaluate BNC
news-medical.net — “QR Pharma, Inc., a developer of novel drugs to treat Alzheimer's disease (AD), announced today that the United States Food and Drug Administration (FDA) has accepted the Investigational New Drug application (IND) to begin human clinical trials and evaluate the safety and efficacy of the company's second product, bisnorcymserine (BNC).” View full resource at news-medical.net
Most Recently Shared on December 3, 2010 at 5:22 am By:
FDA accepts IND application to initiate human clinical trial to evaluate BNC: QR Pharma, Inc., a developer of no... http://bit.ly/fusWDu
InSite Vision Commences Phase 1/2 Clinical Study Of ISV-303 For Post-Surgical Ocular Pain And Swelling
medicalnewstoday.com — “InSite Vision Incorporated (OTCBB:INSV), a company developing novel ophthalmic therapeutics, announced the initiation of a Phase 1/2 clinical trial of ISV-303, a topical anti-inflammatory product” View full resource at medicalnewstoday.com
Most Recently Shared on August 25, 2010 at 1:00 pm By:
InSite Vision Commences Phase 1/2 Clinical Study Of ISV-303 For Post-Surgical Ocular Pain And Swelling http://mnt.to/3HNr #eyehealth
DBV Technologies Receives IND Clearance From FDA To Begin Clinical Trial In Peanut Allergy
medicalnewstoday.com — “DBV Technologies (DBV), a biotech company specializing in food allergy with innovative products for diagnosis and treatment, announced the U.S. Food and Drug Administration (FDA) has accepted its” View full resource at medicalnewstoday.com
Most Recently Shared on July 8, 2010 at 10:20 am By:
DBV Technologies Receives IND Clearance From FDA To Begin Clinical Trial In Peanut Allergy http://mnt.to/3FPQ #allergy
Treat Pain with Essential oils........more than just a remedy for pain whether acute or chronic. - The OilMD Wellness Network
oilmdwellnessnetwork.ning.com — “This product seems like Sports Trauma Ease by the oilMDAbstract Objective: Essential oxygen oil (OxyRub from CreoMed Inc., Naples, FL, U.S.A.) is a novel topical analgesic currently commercially available in Europe and now available in the U.S.A. It represents an important alternative to other treatments (nonsteroidal anti-inflammatory drugs, acetaminophen, menthol, camphor) for managing mild to moderate acute and chronic pain. Several clinical trials of this oil will be reviewed. Results: One l” View full resource at oilmdwellnessnetwork.ning.com
Most Recently Shared on April 4, 2010 at 3:51 pm By:
James Tad Geiger MD Doctor, CAM, Anesthesiologist, and Physician
Just added a new blog post on The OilMD Wellness Network http://ning.it/cQ2oNw
H1N1 Vaccine Trials in HIV-Infected People - The Body
thebody.com — “Clinical trials of the 2009 H1N1 influenza vaccine have begun among HIV-positive pregnant women to determine if the product safely elicits a protective ...” View full resource at thebody.com
Most Recently Shared on October 13, 2009 at 6:42 pm By:
Biostar Pharmaceuticals, Inc. Receives The Chinese Military Drug Administration Clearance To Begin Clinical Trial For Zushima Analgesic Aerosol Spray
medicalnewstoday.com — “Biostar Pharmaceuticals, Inc. (OTC Bulletin Board: BSPM) (Biostar or the Company), a Xianyang-based developer, manufacturer and supplier of pharmaceutical products and medical nutrients addres” View full resource at medicalnewstoday.com
Most Recently Shared on October 8, 2009 at 1:41 pm By:
MNT Pain News Pain Management and Health News
Biostar Pharmaceuticals, Inc. Receives The Chinese Military Drug Administration Clearance To Begin Clinical Tri.. http://bit.ly/oqX4o
Phase II--Islet Regeneration - TuDiabetes
tudiabetes.com — “From www.diabetesincontrol.com Phase II Begins for a New Islet Regeneration Treatment Exsulin Corporation announces next phase II trial of novel islet regeneration treatment in Type 1 diabetes. Leading diabetes research centers collaborate on new trial designed to further evaluate regeneration treatment for people with Type 1 diabetes. Exsulin Corporation announces the start of a phase II human clinical trial of Exsulin(TM), a peptide drug product aimed at restoring insulin production in peop” View full resource at tudiabetes.com
Most Recently Shared on September 16, 2009 at 7:02 am By:
Type 1 diabetes: Phase II--Islet Regeneration: From www.diabetesincontrol.com Phase II Begins .. http://bit.ly/4BcX76
Anacor Announces Positive Results from Phase 2 Psoriasis Trial | Business Wire
businesswire.com — “PALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals today announced that its second Phase 2 clinical trial of AN2728, an investigational topical anti-inflammatory product candidate, achieved its objective of” View full resource at businesswire.com
Most Recently Shared on February 19, 2009 at 10:39 pm By:
National Psoriasis Foundation Dermatology and Health Organization
Anacor Announces Positive Results from Phase 2 Psoriasis Trial http://tinyurl.com/bewdfn
Advertisement
